SELP and coronary artery disorder: In a previous 12-week clinical trial of coronary heart disease (CHD) or CHD-risk equivalent subjects (n = 959), administration of darapladib, a less potent Lp-PLA2 inhibitor than rilapladib, did not induce a change in biomarkers related to platelet activity (P-selectin, CD40 ligand, or urinary 11-dehydrothromboxane B2) [32].